[Remote] Director, Medical Affairs – US Hereditary Disease at Illumina

United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Genomics, HealthcareIndustries

Requirements

Candidates must be board-certified clinical laboratory molecular geneticists with experience in hereditary disease screening and diagnostic genetic testing. A solid understanding of US medical genetics trends, a wide network of key opinion leaders, and demonstrably deep understanding of next-generation sequencing trends, clinical laboratory practices, and their regulatory oversight are required. A strong record of research and publications in hereditary disease is also necessary.

Responsibilities

The Director, Medical Affairs will execute the medical affairs strategy in the United States for hereditary disease, representing Medical Affairs within cross-functional teams and closely coordinating with company strategic goals. Responsibilities include medical research and evidence generation to drive genomics adoption, supporting commercial team strategies, providing scientific education on hereditary disease genomics, and influencing product development. The role involves providing clinical expertise to commercial groups, guiding R&D product development specifications, and supporting product launch strategies and readiness.

Skills

Medical Affairs

Hereditary Disease

Genomic Technology

Molecular Geneticist

Diagnostic Genetic Testing

Next-Generation Sequencing

Clinical Genomics

Scientific Education

Product Development

Regulatory Affairs

Bioinformatics

Assay Development

Quality Assurance

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters

1998Year Founded

$27.2MTotal Funding

IPOCompany Stage

Venture Capital, BiotechnologyIndustries

5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.

Standardizing proteomics data across platforms could challenge Illumina's data reliability.

Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.

The company offers innovative array-based solutions for DNA, RNA, and protein analysis.

Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.

Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.

Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI

Try Jobo Free